Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NTLA vs DNTH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DNTH Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–2 Matrix Metrics)

DNTH Overall Winner 6-Pillar Tally: NTLA 2 – 4 DNTH Matrix Metrics: NTLA 2 – 5 DNTH

As of Nov 16, 2026, Dianthus Therapeutics, Inc. (DNTH) is the stronger overall head-to-head candidate over Intellia Therapeutics, Inc (NTLA) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). NTLA carries a Unified Composite Score of 49.9/100 (HOLD) at $10.00 (N/M Forward P/E, -826.0% operating margin), whereas DNTH carries 34.1/100 (SELL) at $88.58 (N/M Forward P/E, -8683.9% operating margin).

  • Composite vs. Pillar Nuance: While NTLA currently prints a higher short-term Unified Composite Score (49.9/100 HOLD vs. DNTH 34.1/100 SELL), DNTH captures the overall institutional head-to-head verdict (5–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-8683.9% vs. -826.0% operating margin) and revenue trajectory (+205.6% vs. -48.0% YoY).
  • Technical & Structure Timing Caution: NTLA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.3); meanwhile DNTH trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 57.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NTLA vs DNTH
NTLA NASDAQ
Intellia Therapeutics, Inc
In Vitro & In Vivo Diagnostic Substances
$10.00
+3.09% 1D
Market Cap $1.5B
TTM Revenue $53M
Forward P/E N/M
Beta / 30D Vol 2.30β · 87% Vol
Unified Composite Score
49.9 / 100 HOLD
Tech 47.0 Fund 55.0 Flow 59.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.1%), weak momentum, RSI 39
RSI-14: 39.3 · SMA20: $11.58 · SMA50: $11.86
DNTH NASDAQ Head-to-Head Winner
Dianthus Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$88.58
-3.52% 1D
Market Cap $5.2B
TTM Revenue $2.7M
Forward P/E N/M
Beta / 30D Vol 1.03β · 41% Vol
Unified Composite Score
34.1 / 100 SELL
Tech 8.0 Fund 43.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 57.1 · SMA20: $84.01 · SMA50: $88.08

6-Pillar Scorecard Institutional Category Breakdown (NTLA 2 – 4 DNTH)

Columns: Metric · NTLA · DNTH
1. Valuation Multiples NTLA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 29.1x N/M
2. Growth & Scale DNTH
Revenue Growth (YoY) -48.0% +205.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $53M $2.7M
Market Cap $1.5B $5.2B
3. Profitability & Quality DNTH
Gross Margin N/A 100.0%
Operating Margin -826.0% -8683.9%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -62.6% -22.6%
4. Balance Sheet & Cash Flow DNTH
Cash Generation (TTM) -$358M -$176M
Cash Flow Margin N/A N/A
Net Cash / Leverage $74M Net Debt (0.38x D/E) $54M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DNTH
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 101.3% (78th %ile) 83.5% (7th %ile)
Put/Call OI Skew 0.42x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat NTLA
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NTLA (2) vs DNTH (5)
Institutional Metric NTLA DNTH Criterion Row Edge
Market Capitalization
Scale
$1.5B $5.2B Larger Scale DNTH
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-48.0% +205.6% Higher Growth DNTH
Operating Margin (TTM)
Profitability
-826.0% -8683.9% Higher Margin NTLA
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-62.6% -22.6% Higher ROE DNTH
52-Week Range Position
Momentum
20% ($8–$18) 65% ($34–$118) Stronger Trend DNTH
Beta / 30D Volatility
Risk Regime
2.30β · 87% Vol 1.03β · 41% Vol Lower Realized Risk DNTH
Unified Institutional Score
Composite Signal
49.9 / 100 (HOLD) 34.1 / 100 (SELL) Higher Composite NTLA
Trailing 12M Revenue (USD)
Operating Scale
$53M $2.7M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 29.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$358M ($74M Net Debt (0.38x D/E)) -$176M ($54M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DNTH +35.3 pp
NTLA: -12.43% · DNTH: +22.87%
3M Horizon NTLA +9.55 pp
NTLA: -13.79% · DNTH: -23.34%
6M Horizon DNTH +27.15 pp
NTLA: -21.2% · DNTH: +5.95%
1Y Horizon DNTH +134.17 pp
NTLA: +15.34% · DNTH: +149.51%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period NTLA Revenue DNTH Revenue NTLA Op. Margin DNTH Op. Margin Margin Leader
FY2018 $30M N/A -298.6% N/A NTLA
FY2019 $40M N/A -246.8% N/A NTLA
FY2020 $60M N/A -235.5% N/A NTLA
FY2021 $30M N/A -810.4% N/A NTLA
FY2022 $50M N/A -879.0% N/A NTLA
FY2023 $40M $0M -1420.5% -1704.7% NTLA
FY2024 $60M $10M -923.1% -1633.7% NTLA
FY2025 $70M $0M -651.7% -8739.3% NTLA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NTLA BREAKDOWN
94d in phase · OBV DISTRIBUTION
Current IV 101.3%
IV Percentile 78th %ile
Put/Call OI Skew 0.42x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NTLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DNTH CONSOLIDATION
149d in phase · OBV ACCUMULATION
Current IV 83.5%
IV Percentile 7th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact DNTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NTLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.5B market capitalization and -826.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · CRISPR / Gene Editing
DNTH Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $5.2B market capitalization and -8683.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NTLA vs DNTH Key Questions & Quantitative Answers

As of Nov 16, 2026, Dianthus Therapeutics, Inc. (DNTH) is the stronger overall head-to-head candidate over Intellia Therapeutics, Inc (NTLA) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). NTLA carries a Unified Composite Score of 49.9/100 (HOLD) at $10.00 (N/M Forward P/E, -826.0% operating margin), whereas DNTH carries 34.1/100 (SELL) at $88.58 (N/M Forward P/E, -8683.9% operating margin). Composite vs. Pillar Nuance: While NTLA currently prints a higher short-term Unified Composite Score (49.9/100 HOLD vs. DNTH 34.1/100 SELL), DNTH captures the overall institutional head-to-head verdict (5–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-8683.9% vs. -826.0% operating margin) and revenue trajectory (+205.6% vs. -48.0% YoY). Technical & Structure Timing Caution: NTLA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.3); meanwhile DNTH trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 57.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DNTH leads the Growth & Scale pillar: NTLA posts -48.0% YoY revenue growth and +0.0% YoY earnings growth on $53M TTM revenue (N/A gross margin, -826.0% operating margin), compared with DNTH at +205.6% YoY revenue growth and +0.0% YoY earnings growth on $2.7M TTM revenue (100.0% gross margin, -8683.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), NTLA cumulative revenue shifted +133.3% while DNTH shifted N/A. In operating R&D and SG&A reinvestment, NTLA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DNTH.

NTLA screens cheaper on headline valuation multiples. NTLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 29.1x EV/Revenue (unreported FCF margin), whereas DNTH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NTLA (-62.6% ROE) versus DNTH (-22.6% ROE) capital efficiency.

In options market volatility and institutional positioning, NTLA carries 101.3% implied volatility (78th %ile, Elevated (60th–80th %ile)), a 0.42x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.30β · 87% Vol realized risk). By comparison, DNTH carries 83.5% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.03β · 41% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.